Cellectis SA

NASDAQ:CLLSUnited States

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Contact Information

Headquarters

8, rue de la Croix JarryPARIS, France 75013

Phone

---

Fax

---

Executives

Non-Executive Independent Chairman of the Board

Jean-Pierre Garnier

Chief Executive Officer, Co-Founder, Director, Member of the Executive Board

Andre Choulika

Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director

David Sourdive

Interim Chief Financial Officer, Member of the Executive Committee

Arthur Stril

Chief Human Resource Officer, Executive Vice President, Member of the Executive Committee

Kyung Nam-Wortman